American Journal of Clinical Nutrition, Vol 65, 512-518, Copyright © 1997 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Ornithine alpha-ketoglutarate metabolism after enteral administration in burn patients: bolus compared with continuous infusion

T Le Bricon, C Coudray-Lucas, N Lioret, SK Lim, F Plassart, L Schlegel, JP De Bandt, R Saizy, J Giboudeau and L Cynober
Service de Biochimie A, Hopital St-Antoine, Paris, France.

Ornithine alpha-ketoglutarate (OKG) has been successfully used as an enteral supplement in the treatment of catabolic states, including burn injury. However, specific questions remain unanswered concerning burn patients, including OKG metabolism and metabolite production, appropriate mode of administration, and dose. We thus performed a kinetic study and followed plasma ornithine and OKG metabolite concentrations on day 7 postburn in 42 (35 men, 7 women) consecutive burn patients aged 33 +/- 2 y with a mean (+/-SEM) total burn surface area (TBSA) of 31 +/- 1%. Patients were randomly assigned to receive OKG as a single bolus (10 g; n = 13) or in the form of a continuous gastric infusion (10, 20, or 30 g/d over 21 h; n = 13) or an isonitrogenous control (n = 16). Plasma pharmacokinetics of ornithine followed a one-compartment model with first-order input (r = 0.993, P < 0.005). OKG was extensively metabolized in these patients (absorption constant = 0.028 min-1, elimination half-life = 89 min), with the production of glutamine, arginine, and proline; proline was quantitatively the main metabolite [in OKG bolus, area under the curve (AUC)0-7h: proline, 41.4 +/- 5.6 mmol.min/L; glutamine, 20.4 +/- 5.7 mmol.min/L; and arginine, 7.3 +/- 1.9 mmol.min/L]. Proline production was dose-dependent and quantitatively similar between modes of OKG administration. Glutamine and arginine production were not dose- dependent and were higher in the bolus group than in the infusion group. Overall, the bolus mode of OKG administration appeared to be associated with higher metabolite production compared with continuous infusion in burn patients, especially for glutamine and arginine.

This article has been cited by other articles:

				L. Cynober Pharmacokinetics of Arginine and Related Amino Acids J. Nutr., June 1, 2007; 137(6): 1646S - 1649S. [Abstract] [Full Text] [PDF]

				K. L. Urschel, C. W. Wilkinson, P. B. Pencharz, and R. O. Ball Coadministration of Ornithine and {alpha}-Ketoglutarate Is No More Effective Than Ornithine Alone As an Arginine Precursor in Piglets Enterally Fed an Arginine-Deficient Diet J. Nutr., January 1, 2007; 137(1): 55 - 62. [Abstract] [Full Text] [PDF]

				L. Cynober Ornithine {alpha}-Ketoglutarate as a Potent Precursor of Arginine and Nitric Oxide: A New Job for an Old Friend J. Nutr., October 1, 2004; 134(10): 2858S - 2862S. [Abstract] [Full Text] [PDF]

				P. Furst New Developments in Glutamine Delivery J. Nutr., September 1, 2001; 131(9): 2562S - 2568. [Abstract] [Full Text] [PDF]

				M. Bruce, D. Constantin-Teodosiu, P. L. Greenhaff, L. H. Boobis, C. Williams, and J. L. Bowtell Glutamine supplementation promotes anaplerosis but not oxidative energy delivery in human skeletal muscle Am J Physiol Endocrinol Metab, April 1, 2001; 280(4): E669 - E675. [Abstract] [Full Text] [PDF]

				D. A. De-Souza and L. J. Greene Pharmacological Nutrition After Burn Injury J. Nutr., May 1, 1998; 128(5): 797 - 803. [Abstract] [Full Text]

				J.-P. De Bandt, C. Coudray-Lucas, N. Lioret, S. K. Lim, R. Saizy, J. Giboudeau, and L. Cynober A Randomized Controlled Trial of the Influence of the Mode of Enteral Ornithine alpha -Ketoglutarate Administration in Burn Patients J. Nutr., March 1, 1998; 128(3): 563 - 569. [Abstract] [Full Text]